OncoImmunology · 2016 · 10 citations · 50 references
Life SciencesImmunologyOncologyCancer ImmunologyCellular ImmunologyTumor ImmunologyAntitumor T Cell ResponsesCancer ImmunotherapyCell-mediated ImmunityT Cell BiologyTumor ImmunopathologyTumor-infiltrating LymphocytesAdaptive Antitumor ImmunityAntitumor Immune ActivationCd4 Positive T CellsCd4+ Tumor-infiltrating LymphocytesCell Adhesion ComplexesImmunosuppressive MicroenvironmentT Cell-mediated Tumor KillingTumor Immune Cell Infiltration
Hodgkin lymphoma (HL) presents with a unique histologic pattern. Pathognomonic Hodgkin and Reed-Sternberg (HRS) cells usually account for less than 1% of the tumor and are embedded in a reactive infiltrate mainly comprised of CD4(+) T cells. HRS cells induce an immunosuppressive microenvironment and thereby escape antitumor immunity. To investigate the impact of interactions between HRS cells and T cells, we performed long-term co-culture studies that were further translated into a xenograft model. Surprisingly, we revealed a strong antitumor potential of allogeneic CD4(+) T cells against HL cell lines. HRS and CD4(+) T cells interact by adhesion complexes similar to immunological synapses. Tumor-cell killing was likely based on the recognition of allogeneic major histocompatibility complex class II (MHC-II) receptor, while CD4(+) T cells from MHC-II compatible donors did not develop any antitumor potential in case of HL cell line L428. However, gene expression profiling (GEP) of co-cultured HRS cells as well as tumor infiltration of matched CD4(+) T cells indicated cellular interactions. Moreover, matched CD4(+) T cells could be activated to kill CD30(+) HRS cells when redirected with a CD30-specific chimeric antigen receptor. Our work gives novel insights into the crosstalk between HRS and CD4(+) T cells, suggesting the latter as potent effector cells in the adoptive cell therapy of HL.
50
Plasticity of CD4+ T Cell Lineage Differentiation
Liang Zhou, Mark M. W. Chong, Dan R. Littman · Immunity · 2009 · 1.5K citations · Full text
Life Sciences, Biology, Immunology +11
Melanomas resist T-cell therapy through inflammation-induced reversible dedifferentiation
Jennifer Landsberg, Judith Kohlmeyer, Marcel Renn et al. · Nature · 2012 · 641 citations
Medicine, Immunology, Oncology +14
MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers
Christian Steidl, Sohrab P. Shah, Bruce W. Woolcock et al. · Nature · 2011 · 612 citations